Biologics targeted at TNF: Design, production and challenges

Reumatismo

Volumn 58, Issue 2, 2006, Pages 94-103

  Gatto, Barbara ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Adalimumab; Anti TNF biologics; Biotech derived drugs; Etanercept; Infliximab

Indexed keywords

ADALIMUMAB; CYTOKINE; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; BIOLOGICAL PRODUCT; IMMUNOGLOBULIN G; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ARTHRALGIA; AUTOIMMUNE DISEASE; CROHN DISEASE; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG DETERMINATION; DRUG SCREENING; GENE CONSTRUCT; GENE VECTOR; HUMAN; INFLAMMATION; JOINT SWELLING; MOLECULAR CLONING; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT INDICATION; TREATMENT RESPONSE; DRUG ANTAGONISM; SYNTHESIS;

ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; BIOLOGICAL PRODUCTS; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34249056856     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Ermann J, Fathman CG. Autoimmune diseases: genes, bugs and failed regulation. Nat Immunol 2001; 2: 759-761.
2. Feldmann M. Pathogenesis of arthritis: recent research progress. Nat Immunol 2001; 2: 771-773.
3. Aggarwal BB, Moffat B, Harkins RN. Human lymphotoxin. Production by a lymphoblastoid cell line, purification, and initial characterization. J Biol Chem 1984; 259: 686-691.
4. Aggarwal BB, Kohr WJ, Hass PE, Moffat B, Spencer SA, Henzel WJ, Bringman TS, Nedwin GE, Goeddel DV, Harkins RN. Human tumor necrosis factor. Production, purification, and characterization. J Biol Chem 1985; 260: 2345-2354.
5. Aggarwal BB, Eessalu TE, Hass PE. Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon. Nature 1985; 318: 665-667.
6. Gray PW, Aggarwal BB, Benton CV, Bringman TS, Henzel WJ, Jarrett JA, Leung DW, Moffat B, Ng P, Svedersky LP, et al. Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity. Nature 1984; 312: 721-724.
7. Pennica D, Nedwin GE, Hayflick JS, Seeburg PH, Derynck R, Palladino MA, Kohr WJ, Aggarwal BB, Goeddel DV. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984; 312: 724-729.
8. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003; 3: 745-756.
9. Chan FK-M, Chun HJ, Zheng L, Siegel RM, Bui KL, Lenardo MJ. A Domain in TNF Receptors That Mediates Ligand-Independent Receptor Assembly and Signaling. Science 2000; 288: 2351-2354.
10. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992; 89: 9784-9788.
11. Engelmann H, Novick D, Wallach D. Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem 1990; 265: 1531-1536.
12. Maggon K. Best-selling human medicines 2002-2004. Drug Discov Today 2005; 10: 739-742.
13. Mount C, Featherstone J. Rheumatoid arthritis market. Nat Rev Drug Discov 2005; 4: 11-12.
14. Loetscher H, Pan YC, Lahm HW, Gentz R, Brockhaus M, Tabuchi H, Lesslauer W. Molecular cloning and expression of the human 55 Kd tumor necrosis factor receptor. Cell 1990; 61: 351-359.
15. Smith CA, Davis T, Anderson D, Solam L, Beckmann MP, Jerzy R, Dower SK, Cosman D, Goodwin RG. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 1990; 248: 1019-1023.
16. Goodwin RG, Anderson D, Jerzy R, Davis T, Brannan CI, Copeland NG, Jenkins NA, Smith CA. Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor. Mol Cell Biol 1991; 11: 3020-3026.
17. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2002; 2: 364-371.
18. Feldmann M, Maini RN. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 2003; 9: 1245-1250.
19. Goldenberg MM. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin Ther 1999; 21: 75-87.
20. Jacobs C, Smith C; Immunex Corp, assignee. Methods of lowering active TNF-alpha in mammals using tumor necrosis factor receptor. US patent 5,606,690. 1997.
21. Smith CA, Goodwin RG, Beckmann MP; Immunex Corporation, assignee. DNA encoding tumor necrosis factor-alpha and -beta receptors. US patent 5,395,760. 1995.
22. World Health Organization. Requirements for the use of animal cells as in vitro substrates for the production of biologicals (Requirements for Biological Substance N.50). WHO Technical Report Series 1998; 878: 19-53.
23. World Health Organization. Good manufacturing practices for biological products. WHO Technical Report Series 1992; 822: 20-29.
24. World Health Organization. Guidelines for assuring the quality of pharmaceutical and biological products prepared by recombinant DNA technology. WHO Technical Report Series 1991; 814: 59-70.
25. Carson KL. Flexibility - the guiding principle for antibody manufacturing. Nat Biotechnol 2005; 23: 1054-1058.
26. EMEA. EPAR on Enbrel; 2005.
27. EMEA. EPAR on Remicade; 2005.
28. Meager A, Parti S, Leung H, Peil E, Mahon B. Preparation and characterization of monoclonal antibodies directed against antigenic determinants of recombinant human tumour necrosis factor (rTNF). Hybridoma 1987; 6: 305-311.
29. Moller A, Emling F, Blohm D, Schlick E, Schollmeier K. Monoclonal antibodies to human tumor necrosis factor alpha: in vitro and in vivo application. Cytokine 1990; 2: 162-169.
30. Liang CM, Liang SM, Jost T, Sand A, Dougas I, Allet B. Production and characterization of monoclonal antibodies against recombinant human tumor necrosis factor/cachectin. Biochem Biophys Res Commun 1986; 137: 847-854.
31. Fendly BM, Toy KJ, Creasey AA, Vitt CR, Larrick JW, Yamamoto R, Lin LS. Murine monoclonal antibodies defining neutralizing epitopes on tumor necrosis factor. Hybridoma 1987; 6: 359-370.
32. Bringman TS, Aggarwal BB. Monoclonal antibodies to human tumor necrosis factors alpha and beta: application for affinity purification, immunoassays, and as structural probes. Hybridoma 1987; 6: 489-507.
33. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-497.
34. Exley AR, Cohen J, Buurman W, Owen R, Hanson G, Lumley J, Aulakh JM, Bodmer M, Riddell A, Stephens S, et al. Monoclonal antibody to TNF in severe septic shock. Lancet 1990; 335: 1275-1277.
35. Harlow E, Lane D. Antibodies : a laboratory manual. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 1988.
36. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore MA, Vilcek J, Daddona P, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30: 1443-1453.
37. Siegel SA, Shealy DJ, Nakada MT, Le J, Woulfe DS, Probert L, Kollias G, Ghrayeb J, Vilcek J, Daddona PE. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 1995; 7: 15-25.
38. Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov 2003; 2: 52-62.
39. Lonberg N. Human antibodies from transgenic animals. Nat Biotechnol 2005; 23: 1117-1125.
40. Hoogenboom HR. Selecting and screening recombinant antibody libraries. Nat Biotechnol 2005; 23: 1105-1116.
41. Bain B, Brazil M. Adalimumab. Nat Rev Drug Discov 2003; 2: 693-694.
42. Sidhu S. Phage display in pharmaceutical biotechnology. Curr Opinion Biotechnol 2000; 11: 610-616.
43. Kay BK, Kurakin AV, Hyde-DeRuyscher R. From peptides to drugs via phage display. Drug Discov Today 1998; 3: 370-378.
44. Jespers LS, Roberts A, Mahler SM, Winter G, Hoogenboom HR. Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen. Biotechnology (NY) 1994; 12: 899-903.
45. Salfeld J, Allen D, Hoogenboom H, Kaymakcalan Z, Labkovsky B, Mankovich J, McGuinness b, Roberts A, Sakorafas P, Schoenhaut D, Vaughan T, White M, Wilton A; BASF Aktiengesellschaft, assignee. Human antibodies that bind human TNF alpha. US patent 6,090,382. 2000.
46. Osbourn J, Groves M, Vaughan T. From rodent reagents to human therapeutics using antibody guided selection. Methods 2005; 36: 61-68.
47. EMEA. EPAR on Humira; 2005.
48. Moreland LW, Bate G, Kirkpatrick P. Abatacept. Nat Rev Drug Discov 2006; 5: 185-186.
49. Tsang L. Overhauling oversight - European drug legislation. Nat Biotechnol 2005; 23: 1050-1053.
50. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Cannon GW, Spencer-Green G, Finck BK. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002; 46: 1443-1450.
51. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB, the Etanercept Psoriasis Study Group. Etanercept as Monotherapy in Patients with Psoriasis. N Engl J Med 2003; 349: 2014-2022.
52. News In Brief. Nat Rev Drug Discov 2006; 5: 178-179.
53. Rosen H, Abribat T. The rise and rise of drug delivery. Nat Rev Drug Discov 2005; 4: 381-385.
54. Ainsworth S. Biopharmaceuticals. Chem & Engineering News 2005; 83: 21-29.
55. Committee for medicinal products for human use (CHMP) - EMEA. Guideline on similar biological medicinal products. http://www.emea.eu.int; 2005.
56. Garnick R. Counterpoint: Why biogenerics are a strawman. 2006; 24: 269.